Reneo Pharmaceuticals Inc. (NASDAQ: RPHM)
$1.53
+0.0100 ( +0.66% ) 16.4K
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Market Data
Open
$1.53
Previous close
$1.52
Volume
16.4K
Market cap
$50.80M
Day range
$1.51 - $1.53
52 week range
$0.98 - $9.21
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 67 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 12 | Oct 30, 2023 |
8-k | 8K-related | 76 | Oct 10, 2023 |
4 | Insider transactions | 1 | Aug 29, 2023 |
10-q | Quarterly Reports | 62 | Aug 10, 2023 |
8-k | 8K-related | 14 | Aug 10, 2023 |
4 | Insider transactions | 1 | Jul 27, 2023 |